Arcus Biosciences
RCUS
184 hedge funds and large institutions have $1.36B invested in Arcus Biosciences in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 81 increasing their positions, 54 reducing their positions, and 15 closing their positions.
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
50% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 54
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
6% more funds holding
Funds holding: 173 → 184 (+11)
3% more capital invested
Capital invested by funds: $1.33B → $1.36B (+$35.9M)
0.4% less ownership
Funds ownership: 73.13% → 72.73% (-0.4%)
11% less call options, than puts
Call options by funds: $4.87M | Put options by funds: $5.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$17.6M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$10.1M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$9.5M |
| 5 |
O
OrbiMed
New York
|
+$8.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$32.9M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$11.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.77M |
| 5 |
Morgan Stanley
New York
|
-$6.1M |
RCUS Hedge Fund Activity: Q3 2022 in Review
184 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2022, worth a combined $1.36B — up 2.7% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RCUS positions and 15 closed out — a net gain of 11 holders — while 81 added to existing stakes and 54 trimmed.
The largest buyer was BlackRock, adding an estimated $21.3M. The largest seller was BVF Inc, cutting an estimated $32.9M.
- 184 institutional investors held Arcus Biosciences (RCUS) as of Q3 2022, up from 173 in Q2 2022.
- Funds reported $1.36B of Arcus Biosciences stock for Q3 2022, up 2.7% quarter-over-quarter.
- 26 funds opened new Arcus Biosciences positions in Q3 2022 and 15 closed out, a net change of +11 holders.
- The largest Arcus Biosciences buyer in Q3 2022 was BlackRock, an estimated $21.3M added.
- The largest Arcus Biosciences seller in Q3 2022 was BVF Inc, an estimated $32.9M sold.
Based on aggregated 13F filings for Q3 2022.